Similarly, De Veirman et al. showed that S100A9 acted as a chemotractant for multiple myeloma cells and promoted secretion of inflammatory and pro-myeloma cytokines (TNFa, IL6 and IL10) that could represent a way of reducing tumor development [53]. This evidence concerns the gene S100A9 and neoplasm.